theMednetRegister

Dermatology

Neurology   

Questions discussed in this category

How do you approach managing nausea and GI side effects when initiating methotrexate?
3 Answers available
How will you sequence therapies in dermatomyositis given the results of the ProDERM trial?
Will you still favor starting with steroids and traditional immunosuppressive agents, move IVIG earlier in your treatment strategy, or start with IVIG...
3 Answers available
Does IVIG or subcutaneous Ig interfere with monoclonal antibody therapy (i.e. dupilumab, infliximab, rituximab, etc)?
How should IVIG and either biologic injections or infusions be spaced?
2 Answers available
Would you avoid combining JAK inhibitors with IVIG given the risk of thromboembolism?
4 Answers available
How do you recommend tapering IVIG in patients whose inflammatory myositis has achieved remission?
4 Answers available
Which myositis patients are good candidates for IVIG?
3 Answers available
How long can you treat dermatomyositis with IVIG?
3 Answers available
When tapering moderate to high doses of long term steroids do you routinely monitor for adrenal insufficiency?
Do you attempt to taper fully or maintain at a low dose?
2 Answers available
Would you give checkpoint inhibitor therapy to a cancer patient with known dermatomyositis given the association of checkpoint inhibitor associated myocarditis, myasthenia gravis, and myositis?
6 Answers available
How do you approach the management of patients on lamotrigine who develop a minor rash?
Should one restart lamotrigine or look for an alternative? If no other alternative available, is slow titration vs regular titration preferred?
4 Answers available
How do you approach treating patients with trigeminal trophic syndrome?
2 Answers available
What is your preferred steroid sparing therapy in a patient experiencing a severe checkpoint inhibitor toxicity and not responding to high dose IV steroids?
2 Answers available


Papers discussed in this category

N Engl J Med, 2022 Oct 06
Trial of Intravenous Immune Globulin in Dermatomyositis.
Clinical pharmacokinetics, 2018-12
Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease.
Frontiers in immunology, 2018
Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin.
Clinical immunology (Orlando, Fla.), 2020 Jul 15
The potential impact of timing of IVIG administration on the efficacy of rituximab for immune tolerance induction for patients with Pompe disease.
The Pediatric infectious disease journal, 2018 Oct
Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2017 Nov 03
Successful IVIG treatment without discontinuation of TNF-α blocker in Guillain-Barre syndrome induced by adalimumab in patient with Crohn's disease.
The New England journal of medicine, 1993-12-30
A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.

Related Topics in Dermatology

Copyright © 2024 theMednet
All Rights Reserved.